菜单
Suggests administering 25-75 mg hydrocortisone per 24 hours for 1-2 days in patients with adrenal insufficiency undergoing minor to moderate surgical stress. Triggers include patient undergoing minor to moderate surgery with known or suspected adrenal insufficiency.
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
基于 SOC 职业分类
Drug-interaction and co-medication adjustment reference for a child on Genryzon (somatrogon, weekly long-acting growth hormone). Covers glucocorticoids, insulin and oral hypoglycaemics, thyroxine, oral estrogen, and CYP3A4-metabolised drugs (sex steroids, corticosteroids, anticonvulsants, ciclosporin). Use when a clinician asks about drug interactions with Genryzon or somatrogon, prescribing another drug in a child on GH, girl on Genryzon starting OCP, diabetic child starting GH, adjusting hydrocortisone on GH, or CYP3A4 concerns with somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
Titrate Genryzon (somatrogon, weekly long-acting growth hormone) dose in a paediatric GHD patient using serum IGF-1 SDS. Encodes the mandatory 4-days-post-dose sampling rule, the target SDS window, the 15% dose-reduction trigger, and the oral estrogen adjustment. Use when a clinician asks how to titrate somatrogon, when to sample IGF-1 on Genryzon, target IGF-1 SDS on weekly GH, what to do if IGF-1 is too high on somatrogon, IGF-1 rising on Genryzon, how to adjust GH dose in a girl started on oral OCP, or presents a paediatric GHD case on somatrogon with an IGF-1 value to interpret. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
Bedside prescribing reference for Genryzon (somatrogon, Pfizer India) — the once-weekly long-acting growth hormone for paediatric growth hormone deficiency. Use when a clinician asks how to start Genryzon, how to dose somatrogon in a child, how to switch a child from daily growth hormone to weekly somatrogon, how to inject the Genryzon pen, missed-dose rule for somatrogon, when to stop somatrogon, or needs a monograph-level prescribing decision for a paediatric GHD patient. Applies to children and adolescents ≥3 years of age. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
Pretreatment screening checklist before starting Genryzon (somatrogon, weekly long-acting growth hormone) in a child with confirmed paediatric growth hormone deficiency. Ensures thyroid, adrenal, glucose, ocular, tumour, and Prader-Willi status are checked before the first dose to prevent adrenal crisis, wasted therapy, unmasked hypothyroidism, unrecognised hyperglycaemia, missed intracranial hypertension, or sudden death in PWS. Use when a clinician asks what to check before starting somatrogon, workup before Genryzon, baseline tests for weekly GH, screening for adrenal insufficiency before GH, or is about to prescribe Genryzon in a paediatric GHD case. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
Decide when to stop Genryzon (somatrogon, weekly long-acting growth hormone) in a paediatric GHD patient — the three physiological gates (epiphyseal closure, height velocity <2 cm/year, bone age >14 in girls or >16 in boys) plus the safety-driven stops (active tumour, adult GHD re-evaluation, adverse events). Use when a clinician asks when to stop somatrogon, when to discontinue Genryzon, is the child done with GH, has this child reached final height on GH, transitioning GH from paediatric to adult care, or is reviewing a teenager who has been on Genryzon for years. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
| name | ata-minor-moderate-stress-hc |
| description | Suggests administering 25-75 mg hydrocortisone per 24 hours for 1-2 days in patients with adrenal insufficiency undergoing minor to moderate surgical stress. Triggers include patient undergoing minor to moderate surgery with known or suspected adrenal insufficiency. |
Collect baseline hydrocortisone dose, type and expected duration of surgery, and confirm adrenal insufficiency diagnosis. If patient has adrenal insufficiency and is undergoing minor-moderate surgical stress, proceed to STEP 2; otherwise, use usual maintenance dosing.
Determine if stress dosing is indicated: Yes if adrenal insufficiency present and surgery classified as minor to moderate; No if no adrenal insufficiency or major surgical stress. If yes, proceed to STEP 3; if no, administer usual maintenance glucocorticoid dose.
Select hydrocortisone dose within 25-75 mg/24h based on surgical stress magnitude: 25 mg for minor stress, 50 mg for moderate stress, 75 mg for higher moderate stress. Divide into 2-3 doses daily (highest dose in morning). Plan duration of 1-2 days, then taper to maintenance.
Administer the selected hydrocortisone dose in divided doses for 1-2 days, then reduce to usual maintenance dose while monitoring for signs of over- or under-replacement.
Avoid exceeding 75 mg/24h to prevent Cushingoid effects; do not use dexamethasone in pregnancy; monitor for hyperglycemia, fluid retention; ensure patient has emergency hydrocortisone kit if adrenal insufficiency is known; do not delay stress dosing in suspected adrenal crisis.
A 50-year-old man with secondary adrenal insufficiency undergoing open hernia repair (moderate stress) receives 50 mg hydrocortisone daily (25 mg AM, 25 mg PM) for 2 days, then resumes his usual 20 mg daily dose.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118
